Novel Antibiotics Approved by the FDA (2022–2025)
Mechanisms, Applications, and Clinical Relevance
DOI:
https://doi.org/10.33043/utbajxngx7xKeywords:
Antimicrobial resistance (AMR), FDA Approval, Drug development, Antibiotic development, Artificial intelligence (AI)Abstract
Antimicrobial resistance (AMR) is a growing global health crisis, emphasizing the urgent need for new antibiotics. Despite high costs and long development timelines, several novel antibiotics were approved by the U.S. Food and Drug Administration (FDA) between 2022 and 2025. This review summarizes the antibiotic discovery process, the FDA approval pipeline, and highlights key novel agents including Voquezna, Xacduro, Orlynvah, Zevtera, Exblifep, and Blujepa. These therapies employ diverse strategies to achieve selective toxicity, such as inhibition of bacterial cell wall synthesis, β-lactamase activity, and DNA replication, as well as modulation of host-pathogen environments, while limiting damage to host tissues. This review highlights their mechanisms of action, approved clinical indications, and safety profiles, and evaluates their clinical relevance in treatment of infections caused by multidrug-resistant pathogens. Lastly, we discuss the implications of these recent approvals for the future of antibiotic development and emphasize the continued need for sustained investment and innovation to address the growing AMR crisis.
Downloads
References
Adnan, S., Paterson, D. L., Lipman, J., & Roberts, J. A. (2013). Ampicillin/sulbactam: its potential use in treating infections in critically ill patients. International Journal of Antimicrobial Agents, 42(5), 384–389. https://doi.org/10.1016/J.IJANTIMICAG.2013.07.012
Akhavan, B. J., Khanna, N. R., & Vijhani, P. (2023). Amoxicillin. Helicobacter Pylori, 497–506. https://doi.org/10.1007/978-981-97-0013-4_40
Antimicrobial Resistance Facts and Stats | Antimicrobial Resistance | CDC. (n.d.). Retrieved March 19, 2025, from https://www.cdc.gov/antimicrobial-resistance/data-research/facts-stats/index.html
Antimicrobial Resistance Research & Development - AMR Action Fund. (n.d.). Retrieved April 15, 2025, from https://www.amractionfund.com/
Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. (n.d.).
Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., Huang, J., Jones, E., Jones, J., Brown, K. K., Lewis, C. J., May, E. W., Saunders, M. R., Singh, O., Spitzfaden, C. E., … Gwynn, M. N. (2010). Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature, 466(7309), 935–940. https://doi.org/10.1038/NATURE09197;SUBJMETA=1290,154,22,2420,309,326,555,631;KWRD=ANTIBIOTICS,STRUCTURE-BASED+DRUG+DESIGN,TARGET+IDENTIFICATION
Benito, B. M., Nyssen, O. P., & Gisbert, J. P. (2024). Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First-Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta-Analysis. Helicobacter, 29(6). https://doi.org/10.1111/HEL.13148,
Bérdy, J. (2005). Bioactive Microbial Metabolites. The Journal of Antibiotics 2005 58:1, 58(1), 1–26. https://doi.org/10.1038/ja.2005.1
BV, P., & M, G. (2025). Ampicillin/Sulbactam. Drugs of Today, 24(3), 169–174. https://doi.org/10.2165/00128415-199405090-00014
Chu, J., Wang, Y., Zhao, B., Zhang, X. ming, Liu, K., Mao, L., & Kalamiyets, E. (2019). Isolation and identification of new antibacterial compounds from Bacillus pumilus. Applied Microbiology and Biotechnology, 103(20), 8375–8381. https://doi.org/10.1007/S00253-019-10083-Y/FIGURES/4
Church, N. A., & McKillip, J. L. (2021). Antibiotic resistance crisis: challenges and imperatives. Biologia, 76(5), 1535–1550. https://doi.org/10.1007/S11756-021-00697-X/METRICS
Cillóniz, C., Dominedò, C., Garcia-Vidal, C., & Torres, A. (2019). Ceftobiprole for the treatment of pneumonia. Revista Española de Quimioterapia, 32(Suppl 3), 17. https://pmc.ncbi.nlm.nih.gov/articles/PMC6755349/
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) | NIAID: National Institute of Allergy and Infectious Diseases. (n.d.). Retrieved April 15, 2025, from https://www.niaid.nih.gov/research/carb-x
Conly, J. M., & Johnston, B. L. (2005). Where are all the new antibiotics? The new antibiotic paradox. The Canadian Journal of Infectious Diseases & Medical Microbiology, 16(3), 159. https://doi.org/10.1155/2005/892058
David, L., Brata, A. M., Mogosan, C., Pop, C., Czako, Z., Muresan, L., Ismaiel, A., Dumitrascu, D. I., Leucuta, D. C., Stanculete, M. F., Iaru, I., & Popa, S. L. (2021). Artificial Intelligence and Antibiotic Discovery. Antibiotics, 10(11), 1376. https://doi.org/10.3390/ANTIBIOTICS10111376
Devi, S., Sharma, M., & Manhas, R. K. (2023). Purification and biological analysis of antimicrobial compound produced by an endophytic Streptomyces sp. Scientific Reports, 13(1), 15248. https://doi.org/10.1038/S41598-023-41296-X
Drug Trials Snapshots: EXBLIFEP | FDA. (n.d.). Retrieved April 16, 2025, from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-exblifep
Drugs@FDA: FDA-Approved Drugs. (n.d.-a). Retrieved April 24, 2025, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Drugs@FDA: FDA-Approved Drugs. (n.d.-b). Retrieved July 25, 2025, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
ECDC/EMEA Joint Technical Report: The bacterial challenge: time to react. (n.d.). Retrieved April 13, 2025, from https://www.ecdc.europa.eu/en/publications-data/ecdcemea-joint-technical-report-bacterial-challenge-time-react
Fathima, S. A., Arafath, A. Y., Prathiviraj, R., Hassan, S., Kiran, G. S., & Selvin, J. (2025). Bioactive Fraction of Streptomyces thinghirensis MSA1 Effectively Inhibits Biofilm Forming Clinically Significant AMR Pathogens. Current Microbiology, 82(6), 234. https://doi.org/10.1007/S00284-025-04214-0
FDA. (n.d.). FDA Approves New Antibiotic for Three Different Uses. Retrieved April 15, 2025, from https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses
FDA (n.d.). HIGHLIGHTS OF PRESCRIBING INFORMATION. Retrieved April 14, 2025, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218275s000lbl.pdf.
Fedorenko, V., Genilloud, O., Horbal, L., Marcone, G. L., Marinelli, F., Paitan, Y., & Ron, E. Z. (2015). Antibacterial Discovery and Development: From Gene to Product and Back. BioMed Research International, 2015, 591349. https://doi.org/10.1155/2015/591349
Fishman, C., Rae, J. M. C., Posobiec, L. M., Laffan, S. B., Lerman, S. A., Pearson, N., Janmohamed, S., Dumont, E., Nunn-Floyd, D., & Stanislaus, D. J. (2022). Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Antimicrobial Agents and Chemotherapy, 66(11). https://doi.org/10.1128/AAC.00483-22,
Gajdács, M. (2019). The Continuing Threat of Methicillin-Resistant Staphylococcus aureus. Antibiotics, 8(2), 52. https://doi.org/10.3390/ANTIBIOTICS8020052
Ganesh, B., Banerjee, A., & Guruprasad, L. (2025). Evaluating the ability of in silico identified hit compounds to bind Staphylococcus aureus LcpASA using steered molecular dynamics simulations. Molecular Diversity. https://doi.org/10.1007/S11030-025-11155-0,
Gibson, E. G., Bax, B., Chan, P. F., & Osheroff, N. (2019). Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase. ACS Infectious Diseases, 5(4), 570. https://doi.org/10.1021/ACSINFECDIS.8B00315
Hamid, M. N., & Friedberg, I. (2018). Identifying antimicrobial peptides using word embedding with deep recurrent neural networks. Bioinformatics, 35(12), 2009. https://doi.org/10.1093/BIOINFORMATICS/BTY937
Hurley, A., Chevrette, M. G., Acharya, D. D., Lozano, G. L., Garavito, M., Heinritz, J., Balderrama, L., Beebe, M., Denhartog, M. L., Corinaldi, K., Engels, R., Gutierrez, A., Jona, O., Putnam, J. H. I., Rhodes, B., Tsang, T., Hernandez, S., Bascom-Slack, C., Blum, J. E., … Handelsman, J. (2021). Tiny earth: A big idea for stem education and antibiotic discovery. MBio, 12(1), 1–7. https://doi.org/10.1128/MBIO.03432-20
Ierardi, E., Losurdo, G., Fortezza, R. F. La, Principi, M., Barone, M., & Leo, A. Di. (2019). Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World Journal of Gastroenterology, 25(34), 5097–5104. https://doi.org/10.3748/WJG.V25.I34.5097,
Ierardi, E., Losurdo, G., Mileti, A., Paolillo, R., Giorgio, F., Principi, M., & Di Leo, A. (2020). The puzzle of coccoid forms of helicobacter pylori: Beyond basic science. Antibiotics, 9(6), 1–14. https://doi.org/10.3390/ANTIBIOTICS9060293,
Kabbara, W. K., Sadek, E., & Mansour, H. (2025). Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii–Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2025(1). https://doi.org/10.1155/CJID/2001136,
Kaye, K. S., Belley, A., Barth, P., Lahlou, O., Knechtle, P., Motta, P., & Velicitat, P. (2022). Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. JAMA, 328(13), 1304. https://doi.org/10.1001/JAMA.2022.17034
Keam, S. J. (2024). Cefepime/Enmetazobactam: First Approval. Drugs, 84(6), 737–744. https://doi.org/10.1007/S40265-024-02035-2/METRICS
Liu, L., & Nahata, M. C. (2023). Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. Annals of Pharmacotherapy, 57(10), 1185–1197. https://doi.org/10.1177/10600280221149708,
Matsumoto, H., Shiotani, A., & Graham, D. Y. (2019). Current and Future Treatment of Helicobacter pylori Infections. Advances in Experimental Medicine and Biology, 1149, 211–225. https://doi.org/10.1007/5584_2019_367,
McLeod, S. M., Shapiro, A. B., Moussa, S. H., Johnstone, M., McLaughlin, R. E., De Jonge, B. L. M., & Millera, A. A. (2018). Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel β-lactamase inhibitor ETX2514 in clinical isolates of acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 62(2). https://doi.org/10.1128/AAC.01576-17,
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., Moreira, R., Li, Y., Luzhetskyy, A., Medema, M. H., Pernodet, J. L., Stadler, M., Tormo, J. R., Genilloud, O., Truman, A. W., … Müller, R. (2021). Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry 2021 5:10, 5(10), 726–749. https://doi.org/10.1038/s41570-021-00313-1
Moussa, S. H., Shapiro, A. B., McLeod, S. M., Iyer, R., Carter, N. M., Tsai, Y. K., Kristopher Siu, L., & Miller, A. A. (2023). Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 67(11). https://doi.org/10.1128/AAC.00665-23/SUPPL_FILE/AAC.00665-23-S0002.XLSX
New Drug Application (NDA) | FDA. (n.d.). Retrieved April 7, 2025, from https://www.fda.gov/drugs/types-applications/new-drug-application-nda
Novel Drug Approvals for 2025 | FDA. (n.d.). Retrieved April 23, 2025, from https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
Oviatt, A. A., Gibson, E. G., Huang, J., Mattern, K., Neuman, K. C., Chan, P. F., & Osheroff, N. (2024). Interactions between Gepotidacin and Escherichia coli Gyrase and Topoisomerase IV: Genetic and Biochemical Evidence for Well-Balanced Dual-Targeting. ACS Infectious Diseases, 10(4), 1137–1151. https://doi.org/10.1021/ACSINFECDIS.3C00346/ASSET/IMAGES/LARGE/ID3C00346_0011.JPEG
Papp-Wallace, K. M., McLeod, S. M., & Miller, A. A. (2023). Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. Clinical Infectious Diseases, 76(Suppl 2), S194–S201. https://doi.org/10.1093/CID/CIAD095,
Parvaiz, N., Ahmad, F., Yu, W., MacKerell, A. D., & Azam, S. S. (2021). Discovery of beta-lactamase CMY-10 inhibitors for combination therapy against multi-drug resistant Enterobacteriaceae. PLoS ONE, 16(1), e0244967. https://doi.org/10.1371/JOURNAL.PONE.0244967
Patel, P. H., & Hashmi, M. F. (2025). Macrolides. StatPearls. https://pubmed.ncbi.nlm.nih.gov/31855339/
Penwell, W. F., Shapiro, A. B., Giacobbe, R. A., Gu, R. F., Gao, N., Thresher, J., McLaughlin, R. E., Huband, M. D., DeJonge, B. L. M., Ehmann, D. E., & Miller, A. A. (2015). Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 59(3), 1680–1689. https://doi.org/10.1128/AAC.04808-14,
Pfaller, M. A., Flamm, R. K., Mendes, R. E., Streit, J. M., Smart, J. I., Hamed, K. A., Duncan, L. R., & Sader, H. S. (2018). Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016. Antimicrobial Agents and Chemotherapy, 63(1), e01566-18. https://doi.org/10.1128/AAC.01566-18
Queenan, A. M., Shang, W., Kania, M., Page, M. G. P., & Bush, K. (2007). Interactions of Ceftobiprole with β-Lactamases from Molecular Classes A to D. Antimicrobial Agents and Chemotherapy, 51(9), 3089. https://doi.org/10.1128/AAC.00218-07
Ribeiro da Cunha, B., Fonseca, L. P., & Calado, C. R. C. (2021). Simultaneous elucidation of antibiotic mechanism of action and potency with high-throughput Fourier-transform infrared (FTIR) spectroscopy and machine learning. Applied Microbiology and Biotechnology, 105(3), 1269–1286. https://doi.org/10.1007/S00253-021-11102-7/FIGURES/7
Robbins, N., Koch, S. E., Tranter, M., & Rubinstein, J. (2012). The history and future of probenecid. Cardiovascular Toxicology, 12(1), 1–9. https://doi.org/10.1007/S12012-011-9145-8,
Ross, J. D. C., Wilson, J., Workowski, K. A., Taylor, S. N., Lewis, D. A., Gatsi, S., Flight, W., Scangarella-Oman, N. E., Jakielaszek, C., Lythgoe, D., Powell, M., Janmohamed, S., Absalon, J., & Perry, C. (2025). Oral Gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. The Lancet, 405(10489), 1608–1620. https://doi.org/10.1016/S0140-6736(25)00628-2
Sabih, A., & Leslie, S. W. (2024). Complicated Urinary Tract Infections. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK436013/
Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. A. (2023). Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare, 11(13), 1946. https://doi.org/10.3390/HEALTHCARE11131946
Scarpignato, C., & Hunt, R. H. (2024). Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. Current Gastroenterology Reports, 26(11), 273. https://doi.org/10.1007/S11894-024-00939-3
Schaefer, K., Matano, L. M., Qiao, Y., Kahne, D., & Walker, S. (2017). In vitro reconstitution demonstrates the cell wall ligase activity of LCP proteins. Nature Chemical Biology, 13(4), 396–401. https://doi.org/10.1038/NCHEMBIO.2302,
Scheeren, T. W. (2015). Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia. Future Microbiology, 10(12), 1913–1928. https://doi.org/10.2217/FMB.15.115
Shapiro, A. B., Moussa, S. H., McLeod, S. M., Durand-Réville, T., & Miller, A. A. (2021). Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam. Frontiers in Microbiology, 12. https://doi.org/10.3389/FMICB.2021.709974,
Shi, J., Cheng, J., Liu, S., Zhu, Y., & Zhu, M. (2024). Acinetobacter baumannii: an evolving and cunning opponent. Frontiers in Microbiology, 15. https://doi.org/10.3389/FMICB.2024.1332108,
Small World Initiative / Antibiotic Resistance / Crowdsourcing New Antibiotics / Inspiring Science Students. (n.d.). Retrieved April 15, 2025, from https://www.smallworldinitiative.org/
So, A. D., & Shah, T. A. (2014). New business models for antibiotic innovation. Upsala Journal of Medical Sciences, 119(2), 176–180. https://doi.org/10.3109/03009734.2014.898717
Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackerman, Z., Tran, V. M., Chiappino-Pepe, A., Badran, A. H., Andrews, I. W., Chory, E. J., Church, G. M., Brown, E. D., Jaakkola, T. S., Barzilay, R., & Collins, J. J. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688. https://doi.org/10.1016/J.CELL.2020.01.021
Suvarna, D. V. (2010). Phase IV of Drug Development. Perspectives in Clinical Research, 1(2), 57. https://doi.org/10.4103/2229-3485.71852
Syed, Y. Y. (2014). Ceftobiprole medocaril: A review of its use in patients with hospital- or community-acquired pneumonia. Drugs, 74(13), 1523–1542. https://doi.org/10.1007/S40265-014-0273-X/METRICS
The Global Antibiotic Research and Development Partnership (GARDP). (n.d.). Retrieved April 15, 2025, from https://www.who.int/groups/gardp
Van Norman, G. A. (2016). Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs. JACC: Basic to Translational Science, 1(3), 170. https://doi.org/10.1016/J.JACBTS.2016.03.002
Wagenlehner, F., Perry, C. R., Hooton, T. M., Scangarella-Oman, N. E., Millns, H., Janmohamed, S., Kramer, M., Kushner, P., Powell, M., Jarvis, E., Dennison, J., Sheets, A., Butler, D., & Breton, J. (2025). Plain language summary: efficacy and safety of Gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection. Future Microbiology, 20(4), 265. https://doi.org/10.1080/17460913.2025.2460387
Zhanel, G. G., Pozdirca, M., Golden, A. R., Lawrence, C. K., Zelenitsky, S., Berry, L., Schweizer, F., Bay, D., Adam, H., Zhanel, M. A., Lagacé-Wiens, P., Walkty, A., Irfan, N., Naber, K., Lynch, J. P., & Karlowsky, J. A. (2022). Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs, 82(5), 533–557. https://doi.org/10.1007/S40265-022-01688-1,
Zhang, M. ming, Wang, M. ding, Yang, S. yu, Hu, J. qiang, Zhu, B. qiang, Wei, Y. kui, Zhang, C. lan, & Long, E. wu. (2025). The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis. Journal of Infection and Public Health, 18(7). https://doi.org/10.1016/J.JIPH.2025.102768,
Zimmerman, J., Giuliano, C., & Kale-Pradhan, P. B. (2024). Ceftobiprole Medocaril: A New Fifth-Generation Cephalosporin. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241293773
Zoffmann, S., Vercruysse, M., Benmansour, F., Maunz, A., Wolf, L., Blum Marti, R., Heckel, T., Ding, H., Truong, H. H., Prummer, M., Schmucki, R., Mason, C. S., Bradley, K., Jacob, A. I., Lerner, C., Araujo del Rosario, A., Burcin, M., Amrein, K. E., & Prunotto, M. (2019). Machine learning-powered antibiotics phenotypic drug discovery. Scientific Reports, 9(1), 5013. https://doi.org/10.1038/S41598-019-39387-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Mana Shahrokhi, Rheanna E. Walther
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
By submitting to Fine Focus, the author(s) agree to the terms of the Author Agreement. Beginning in Fall 2018, all authors retain copyrights associated with their article contributions and agree to make such contributions available under a Creative Commons Attribution-NonCommercial 4.0 International license upon publication in Fine Focus. Copyrights to articles published prior to Fall 2018 have been transferred from the authors to Fine Focus.
